The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.
Sourisseau M, Faure E, Béhal H, Chauvet P, Srour M, Capes A, Coiteux V, Magro L, Alfandari S, Alidjinou EK, Simon N, Vuotto F, Karam M, Faure K, Yakoub-Agha I, Beauvais D.
Sourisseau M, et al. Among authors: behal h.
Blood Adv. 2023 Mar 14;7(5):856-865. doi: 10.1182/bloodadvances.2022008667.
Blood Adv. 2023.
PMID: 36350752
Free PMC article.